Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6atac small nuclear 26, pseudogene (RNU6ATAC26P) is a pseudogene that is related to the U6atac small nuclear RNA (snRNA) family, which is involved in the minor spliceosome machinery required for the splicing of a small class of introns known as U12-type introns[1][3]. However, as a pseudogene, RNU6ATAC26P is considered nonfunctional: it does not encode a functional protein or RNA product required for spliceosomal activity, and there is no evidence that it serves as a therapeutic target or has a defined molecular role in disease. Its main significance lies in genome annotation rather than functional genomics or biomedical relevance. There are no drugs, mechanism of action profiles, or safety issues associated with this entity. The presence of the term "pseudogene" means it has lost the function of the original gene. While some pseudogenes may be transcribed or even translated, this is rare and usually functionally irrelevant; there is no evidence that RNU6ATAC26P has such a role. This entity is not considered a druggable or therapeutic target and is not typically referenced in clinical or basic biomedical contexts[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 26, pseudogene (RNU6ATAC26P).